RBC Capital analyst Randall Stanicky maintained a Buy rating on Pacira Pharmaceuticals (PCRX) on May 7 and set a price target of $56.00. The company’s shares closed last Friday at $42.07.
According to TipRanks.com, Stanicky has 0 stars on 0-5 stars ranking scale with an average return of -11.7% and a 26.1% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Teva Pharmaceutical Industries, Osmotica Pharmaceuticals, and Amneal Pharmaceuticals.
Pacira Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $54.92, implying a 26.9% upside from current levels. In a report issued on April 27, Wedbush also reiterated a Buy rating on the stock with a $85.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $51.36 and a one-year low of $27.46. Currently, Pacira Pharmaceuticals has an average volume of 735.1K.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of PCRX in relation to earlier this year. Most recently, in March 2020, Gary Pace, a Director at PCRX bought 21,736 shares for a total of $96,845.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pacira Biosciences, Inc. develops and manufactures injectable therapeutic products. The firm engages in the development, commercialization and manufacture of pharmaceutical products for use in postsurgical outcomes for acute care practitioners and their patients. Its flagship product, EXPAREL, redefines pain management after surgery as an opioid-free alternative indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was founded in December 2006 and is headquartered in Parsippany, NJ.
